Barco NV BAR.BR
Composite 52/100; the shares have moved about 21% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 13/100 — a strong mark against it.
Balance-sheet strength ranks 79/100 — a strong point in its favour. Income ranks 71/100 — a moderate point in its favour. Valuation ranks 64/100 — a moderate point in its favour.
Momentum ranks 13/100 — a strong mark against it. Growth ranks 36/100 — a moderate mark against it. Quality ranks 50/100 — a slight mark against it.
What the company does Barco NV designs and sells visualization, collaboration, and networking technologies across entertainment, enterprise, and healthcare markets. Its offerings include medical displays, video walls, projectors, and room-conferencing systems used in radiology, surgery, and enterprise collaboration.
Key financials Barco’s trailing twelve-month margins show gross profit at 39.8%, operating at 0.3%, and net at 4.7%. ROE is 6.4%, ROA 2.6%, and ROCE 18.0%. Revenue and EPS growth are negative at -8.0% and -3.7%, respectively. The balance sheet is conservative with debt/equity at 0.20 and interest coverage of 22.88.
Stock health Momentum is weak with 3m -11.92%, 6m -28.54%, and 12m -37.85% returns. The RSI(14) is 37.40, indicating oversold conditions. Quality scores are low (40.7/100), growth is poor (17.9/100), and momentum is weak (14.9/100), offset partially by strong valuation (66.7/100) and income (72.8/100).
Price vs fair value The stock trades at a discount of 24.50% versus our fair-value estimate of 9.85 and at a discount of 41.59% versus the analyst 12-month target of 11.20. - Net margin of 4.7% and operating margin of 0.3% signal profitability headwinds (Key Financials). - Revenue and EPS growth are negative at -8.0% and -3.7% (Key Financials). - Momentum is deeply negative over 3m, 6m, and 12m periods (Momentum). - Quality score of 40.7/100 indicates weak fundamentals (Sideravia Score).
Looking forward Forward P/E of 12.05 and PEG of 0.43 suggest valuation support, while a dividend yield of 6.9% may appeal to income-focused investors. Execution on growth initiatives in healthcare and enterprise segments will be key to closing the valuation gap.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.